1,358 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Are You Looking for a Top Momentum Pick? Why Euronav NV (EURN) is a Great Choice http://www.zacks.com/stock/news/575334/are-you-looking-for-a-top-momentum-pick-why-euronav-nv-eurn-is-a-great-choice?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-575334 Oct 21, 2019 - Does Euronav NV (EURN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Schlumberger NV (SLB) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/10/18/schlumberger-nv-slb-q3-2019-earnings-call-transcri.aspx?source=iedfolrf0000001 Oct 18, 2019 - SLB earnings call for the period ending September 30, 2019.
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings http://www.zacks.com/stock/news/571262/factors-setting-the-tone-for-novartis-nvs-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-571262 Oct 18, 2019 - Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD http://www.zacks.com/stock/news/569743/novartis-jakavi-meets-primary-goal-in-phase-iii-for-gvhd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-569743 Oct 17, 2019 - Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Roche Posts Solid Sales for First 9 Months of '19, Ups View http://www.zacks.com/stock/news/569605/roche-posts-solid-sales-for-first-9-months-of-19-ups-view?cid=CS-ZC-FT-analyst_blog|earnings_article-569605 Oct 17, 2019 - Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
ASML HOLDING NV (ASML) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/10/16/asml-holding-nv-asml-q3-2019-earnings-call-transcr.aspx?source=iedfolrf0000001 Oct 16, 2019 - ASML earnings call for the period ending September 29, 2019.
Roche Announces Positive Late-Stage Data on Rituxan in PV http://www.zacks.com/stock/news/563858/roche-announces-positive-late-stage-data-on-rituxan-in-pv?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-563858 Oct 14, 2019 - Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals http://www.zacks.com/stock/news/559573/pharma-stock-roundup-nvs-new-eye-drug-gets-fda-nod-nvo-gsk-pfe-sign-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-559573 Oct 11, 2019 - FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
Wet AMD Space in Focus: New Drug Approvals & Key Advancements http://www.zacks.com/stock/news/557772/wet-amd-space-in-focus-new-drug-approvals-key-advancements?cid=CS-ZC-FT-analyst_blog|industry_focus-557772 Oct 10, 2019 - The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval http://www.zacks.com/stock/news/556356/novartis-nvs-wet-amd-drug-beovu-obtains-fda-approval?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-556356 Oct 09, 2019 - Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.

Pages: 12345678910...136

<<<Page 5>